Nordic Drugs lanserar ny behandling för torra ögon

Nordic Drugs meddelar CE-märkning för Lacrifill® Canalicular Gel – introducerar en ny behandlingsmöjlighet för torra ögon i Norden.

Nordic Drugs announces that Lacrifill®, a novel therapy for the treatment of dry eye disease, has received CE mark approval. This regulatory milestone, achieved several months ahead of schedule, paves the way for market introduction across the Nordic region and other European countries in the coming months.

Lacrifill® is a cross-linked hyaluronic acid gel developed to temporarily block tear drainage by occluding the canalicular system. This mechanism helps preserve the eye’s natural tear film, offering a personalized and long-lasting approach to managing dry eye. The in-office procedure fully fills the canalicular system, delivering therapeutic effects for up to six months.

Dry eye disease is one of the most common ocular conditions, affecting up to 30% of the European population, with prevalence expected to rise due to aging demographics and increased screen use. Management of dry eye is particularly challenging in the context of certain ocular surgeries such as cataract and refractive surgery, where effective tear film support is crucial for recovery and comfort.

Following its successful launch in the United States, Nordic Drugs is preparing to introduce Lacrifill® in Sweden, Norway, Denmark, and Finland, strengthening access to innovative dry eye care in the Nordic region.

“The CE mark for Lacrifill® is an important step in making this innovative treatment accessible to patients across the Nordics. Dry eye disease is a significant clinical challenge here, and we are proud to bring a solution that offers long-lasting relief through a simple, in-office procedure,” said Henna Saarialho, General Manager at Nordic Drugs. “We look forward to supporting eye care professionals across the region as we prepare for the launch.”

Commercial preparations are currently underway, and further details regarding availability and distribution in the Nordic countries will be announced closer to the launch date.